<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.18.1" />


<title>Early Drug Development - A Hugo website</title>
<meta property="og:title" content="Early Drug Development - A Hugo website">



  







<link rel="stylesheet" href="../../../../css/fonts.css" media="all">
<link rel="stylesheet" href="../../../../css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="../../../../" class="nav-logo">
    <img src="../../../../images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="../../../../about/">About</a></li>
    
    <li><a href="https://github.com/rstudio/blogdown">GitHub</a></li>
    
    <li><a href="https://twitter.com/rstudio">Twitter</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    
    <span class="article-duration">2 min read</span>
    

    <h1 class="article-title">Early Drug Development</h1>

    
    <span class="article-date">0001/01/01</span>
    

    <div class="article-content">
      

<p>이전 학기에 Tozer를 마치고 새로운 책으로 Book reading을 시작하게 되었습니다. 아래와 같이 요약하고자 합니다.</p>

<p><a href="https://www.amazon.com/Early-Drug-Development-First-Human/dp/0470170867">Early Drug Development - Strategies and Routes to First-in-Human Trials by Mitchell N. Cayen</a></p>

<p><img src="https://images-na.ssl-images-amazon.com/images/I/51mstpfe5qL._SX329_BO1,204,203,200_.jpg" alt="" /></p>

<p><img src="http://www.drugstorenews.com/sites/drugstorenews.com/files/field_main_image/2016-04/NovelNewDrugs_main.jpg" alt="" /></p>

<h1 id="chapter-1-the-drug-discovery-and-development-scene">Chapter 1. The Drug Discovery and Development Scene</h1>

<h2 id="introduction">Introduction</h2>

<ul>
<li>신약 개발의 어려운 점 서술.</li>
<li>NCE (New Chemical Entity)</li>
<li>&ldquo;Bigger is Better&rdquo; philosophy</li>
<li>Rule of Five (Lipinski) - 5개 이하 hydrogen bon, 10 bond acceptors, &lt; 500kDa</li>
<li>Hit-to-Lead Identification</li>
<li>SAR: Structure-activity compounds</li>
<li>Small molecule to various new entities</li>
<li>Table 1.1 - Some Optimal Characteristics Evaluated During the Discovery Phase for Orally Administered Drugs</li>
<li>Toxicogenomics - Possible alternative to animal tox testing</li>
<li>&ldquo;Can it replace the animal models?&rdquo;</li>
<li>Permeability and transporter assays -&gt; drug uptake into or efflux from the target organ</li>
<li>PK뿐 아니라 PD 측정하면 이상적일 것이다(Extremely useful).</li>
<li>EMEA, FDA, MHLW (Japan)</li>
</ul>

<h2 id="cro-contract-research-organizations">CRO (Contract Research Organizations)</h2>

<ul>
<li>CRO를 잘 골라야 한다. 문화를 잘 관찰</li>
</ul>

<h1 id="chapter-2-adme-strategies-in-lead-optimization">Chapter 2. ADME strategies in lead optimization</h1>

<ul>
<li>speaker: Park</li>
<li>date: 2016-10-25</li>
<li>Lead optimization - several screens to select an NCE with the best overall efficacy, ADME/PK</li>
<li>in silico adme screening</li>
<li>data-based modeling</li>
<li>log P(partition coefficient), log D (log P using buffer at pH7.4) - charge 띈게 많은 것을 고려함.</li>
<li>basic requirements for successful in silico modeling</li>
<li>구조를 입력하면 대사에 대한 정보가 나옴.</li>
<li>Metabolomics - 대사체를 분석하는 것이 많은 정보를 줄 수 있다.</li>
</ul>

<h1 id="chapter-5-chemistry-manufacturing-and-controls">Chapter 5. Chemistry, Manufacturing, and Controls</h1>

<ul>
<li>in vitro pharmacology</li>
<li>Pre-NCE activities and CMC development</li>
<li>Crystal forms - Table 5.5</li>
<li>preformulation</li>
<li>특징화, 제제화</li>
<li>GMP, LBP</li>
<li>특징화되어야 한다.</li>
<li>Toxicology Formulations

<ul>
<li>later Stages of tretm</li>
</ul></li>
</ul>

<h1 id="chapter-7-toxicology-program-to-support-initiation-of-a-clinical-phase-i-program-for-a-new-medicine">Chapter 7. Toxicology Program to Support Initiation of a CLinical Phase I Program For a New Medicine</h1>

<ul>
<li>Nonclinical safety margin</li>
<li>비임상 개발 review시에도 physician이 참가해야 한다.</li>
<li>Inactive ingredients -&gt; FDA approval.</li>
<li>Timely Conduct</li>
<li>Ames - IND 필수 항목. Regulatory submission of IND.</li>
<li>if + in Ames -&gt; similar pharmacologic activity and negative in the Ames assay.</li>
<li>미국 IND, 영국 CTA, 12-18 months</li>
<li>28 days. Maximum duration of dosing that can occur in the human studies</li>
<li>No observable effect level</li>
<li>HNSTD - Highest nonsevere toxic dose - NOAEL보다는 좀더 높다. Severe adverse events가 나타나지 않는 최대의 용량을 말하는 것.</li>
<li>IND - regulatory requirement, guidelines, safety, controlled condition-&gt;synthesized.</li>
<li>pre-FIH toxicity studies - providing a basis for selection of the initial dose</li>
<li><sup>1</sup>&frasl;<sub>10</sub> NOAEL <sup>1</sup>&frasl;<sub>6</sub> non rodent</li>
<li>Toxicology만 받았는데.. 앞으로는 efficacy 측면에서 효과를 보여야 할지도 모른다.</li>
</ul>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="../../../../index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
          <li>
            <a href="https://gohugo.io/" class="footer-links-kudos">Made with <img src="../../../../images/hugo-logo.png" width="22" height="22"></a>
          </li>
        </ul>
      </footer>

    </div>
    

    

    
  </body>
</html>

